{
  "source": "PA-Notification-Tibsovo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1257-9\nProgram Prior Authorization/Notification\nMedication Tibsovo® (ivosidenib)\nP&T Approval Date 9/2018, 6/2019, 6/2020, 6/2021, 10/2021, 10/2022, 10/2023, 1/2024,\n1/2025\nEffective Date 4/1/2025\n1. Background:\nTibsovo® (ivosidenib) is an isocitrate dehydrogenase-1 inhibitor indicated for the treatment of\nadult patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation with relapsed or\nrefractory acute myeloid leukemia (AML) or in combination with azacitidine or as monotherapy\nfor the treatment of newly diagnosed AML in adults who are > 75 years old, or who have\ncomorbidities that preclude the use of intensive induction chemotherapy. Tibsovo is indicated for\nthe treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with\na susceptible IDH1 mutation. Tibsovo is also indicated in adult patients with a susceptible IDH1\nmutation with locally advanced or metastatic cholangiocarcinoma who have previously been\ntreated.\nThe National Cancer Comprehensive Network (NCCN) guideline also recommends the use of\nTibsovo in susceptible IDH1 mutation-positive AML patients who are 60 to 74 years old and\nreceiving Tibsovo as treatment induction when not a candidate for intensive remission induction\ntherapy or declines, or as post-induction therapy following response to previous lower intensity\ntherapy with the same regimen. The NCCN guidelines also recommend the use of Tibsovo in\nIDH1 mutation-positive patients with either conventional (grades 1-3) or dedifferentiated\nchondrosarcoma, recurrent or progressive IDH mutant 1p19q codeleted oligodendroglioma WHO\nGrade 2 or 3, and recurrent or progressive IDH-mutant astrocytoma WHO Grade 2, 3, or 4.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit co",
    "s will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tibsovo will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n1\nB. Acute Myeloid Leukemia (AML)\n1. Initial Authorization\na. Tibsovo will be approved based on all of the following criteria:\n(1) Diagnosis of acute myeloid leukemia (AML)\n-AND-\n(2) AML is IDH1 mutation-positive\n-AND-\n(3) One of the following:\n(a) Disease is relapsed or refractory\n-OR-\n(b) Both of the following:\ni. New diagnosis of AML\n-AND-\nii. One of the following:\n• Patient ≥ 75 years old\n• Patient has comorbidities that preclude the use of intensive induction\nchemotherapy\n• Patient is ≥ 60 years old and not a candidate for or declines intensive\ninduction therapy\n• Patient is ≥ 60 years old and receiving post-induction therapy\nfollowing response to previous lower intensity therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tibsovo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tibsovo therapy\nAuthorization will be issued for 12 months.\nC. Bone Cancer\n1. Initial Authorization\na. Tibsovo will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services Inc.\n2\n(1) Diagnosis of chondrosarcoma\n-AND-\n(2) Susceptible IDH1 mutation-positive\n-AND-\n(3) Disease is one of the following:\n(a) Conventional (grades 1-3)\n(b) Dedifferentiated\nAuthorization will be issued for",
    " Diagnosis of chondrosarcoma\n-AND-\n(2) Susceptible IDH1 mutation-positive\n-AND-\n(3) Disease is one of the following:\n(a) Conventional (grades 1-3)\n(b) Dedifferentiated\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tibsovo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tibsovo therapy\nAuthorization will be issued for 12 months.\nD. Biliary Tract Cancer\n1. Initial Authorization\na. Tibsovo will be approved based on all of the following criteria:\n(1) Diagnosis of cholangiocarcinoma\n-AND-\n(2) Susceptible IDH1 mutation-positive\n-AND-\n(3) Disease is one of the following:\n(a) Locally advanced\n(b) Unresectable\n(c) Metastatic\n-AND-\n(4) Disease has progressed on or after systemic treatment\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n3\n2. Reauthorization\na. Tibsovo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tibsovo therapy\nAuthorization will be issued for 12 months.\nE. Oligodendroglioma\n1. Initial Authorization\na. Tibsovo will be approved based on all of the following criteria:\n(1) Diagnosis of oligodendroglioma\n-AND-\n(2) Disease is recurrent or progressive\n-AND-\n(3) Presence of both of the following:\n(a) IDH1 mutation\n(b) 1p19q codeletion\n-AND-\n(4) Disease is WHO grade 2 or 3\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tibsovo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tibsovo therapy\nAuthorization will be issued for 12 months.\nF. Astrocytoma\n1. Initial Authorization\na. Tibsovo will be approved based on all of the following criteria:\n(1) Diagnosis of astrocytoma\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n4\n(2) Disease is recurrent or progressive\n-AND-\n(3) Presence of IDH1 mutation\n-AND-\n(4) Disease is WHO grade 2, 3, or 4\nAuthorization will be issued for 12 months.\n2. Reauthorizati",
    "hcare Services Inc.\n4\n(2) Disease is recurrent or progressive\n-AND-\n(3) Presence of IDH1 mutation\n-AND-\n(4) Disease is WHO grade 2, 3, or 4\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tibsovo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tibsovo therapy\nAuthorization will be issued for 12 months.\nG. Myelodysplastic Syndromes (MDS)\n1. Initial Authorization\na. Tibsovo will be approved based on all of the following criteria:\n(1) Diagnosis of myelodysplastic syndrome (MDS)\n-AND-\n(2) Disease is relapsed or refractory\n-AND-\n(3) Presence of IDH1 mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tibsovo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tibsovo therapy\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\n© 2025 UnitedHealthcare Services Inc.\n5\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Tibsovo [package insert]. Boston, MA: Servier Pharmaceuticals LLC; October 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed November 25, 2024.\nProg",
    "sovo [package insert]. Boston, MA: Servier Pharmaceuticals LLC; October 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed November 25, 2024.\nProgram Prior Authorization/Notification – Tibsovo (ivosidenib)\nChange Control\n9/2018 New program.\n6/2019 Updated background and criteria to include new indication for newly\ndiagnosed AML in patients ≥ 75 years of age or with comorbidities that\npreclude intensive induction chemotherapy.\n6/2020 Annual review. Added general NCCN recommendations for use\ncriteria. Updated references.\n6/2021 Annual review. Added criteria per NCCN guidelines for\nchondrosarcoma and cholangiocarcinoma. Updated reference.\n10/2021 Updated background and criteria for AML biliary tract cancer to align\nwith both label and NCCN guidelines. Updated references.\n10/2022 Annual review. Added state mandate footnote. Updated background\nand criteria to more closely align with the NCCN guidelines. Updated\nreferences.\n10/2023 Annual review. Added criteria for oligodendroglioma and astrocytoma\nper NCCN guidelines. Updated references.\n1/2024 Updated background and criteria to include new indication for relapsed\nor refractory MDS with a susceptible IDH1 mutation. Updated\nreferences.\n1/2025 Annual review. Updated criteria for oligodendroglioma and\nastrocytoma per NCCN guidelines. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n6"
  ]
}